Company Plans to Initiate Fourth Cohort of ACR-368 Study in H1 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 19 2026
0mins
Should l Buy ACRV?
Building on clinical data and observed biomarker upregulation in serous EC, the company announced today that it plans to initiate a fourth cohort in the ongoing ACR-368 Phase 2b study in the first half of 2026. This arm will enroll all-comer serous EC subjects, similar to Arm 3, but subjects will be treated with ACR-368 monotherapy and otherwise identical inclusion criteria to Arm 3. Company also announced today that it has completed the exploratory Arm 2 of the study which treated BM- EC subjects with less than or equal to3 prior LoT using ACR-368 with ULDG sensitization. Objectives of this arm were achieved, supporting that ULDG may contribute to ACR-368 efficacy in BM- subjects with a favorable tolerability profile.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ACRV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ACRV
Wall Street analysts forecast ACRV stock price to rise
6 Analyst Rating
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 1.330
Low
7.00
Averages
10.50
High
19.00
Current: 1.330
Low
7.00
Averages
10.50
High
19.00
About ACRV
Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision oncology medicines. It uses its precision Generative Phosphoproteomics platform, Acrivon Predictive Precision Proteomics (AP3), to develop its pipeline of oncology drug candidates. Its lead candidate, ACR-368, is a selective small molecule inhibitor which targets CHK1 and CHK2 at sub single-digit nM and single-digit nM potency in intact cells, respectively, in a registrational Phase II trial across multiple solid tumor types. Using its AP3 platform, it has developed a predictive OncoSignature test for ACR-368, called ACR-368 OncoSignature, that can predict patient response to ACR-368 monotherapy and therefore improve the clinical overall response rate (ORR) and has the potential to enable drug development. Its preclinical program, ACR-2316, is advancing in investigational new drug-enabling studies. It is a novel, dual WEE1 and PKMYT1 inhibitor small molecule development candidate.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Acrivon Therapeutics Q4 Earnings Miss Expectations
- Earnings Report: Acrivon Therapeutics reported a Q4 GAAP EPS of -$0.49, missing expectations by $0.01, indicating ongoing challenges in profitability that may affect investor confidence.
- Cash Reserves: As of December 31, 2025, the company had $118.6 million in cash, cash equivalents, and marketable securities, expected to fund operations into Q2 2027, suggesting adequate liquidity in the short term.
- Conference Presentations: Acrivon presented at the TD Cowen 46th Annual Health Care Conference and the ESGO 27th Annual Congress, aiming to enhance visibility among investors and the industry, potentially creating future financing opportunities.
- Market Attention: Seeking Alpha's Quant Rating on Acrivon Therapeutics reflects market scrutiny of its financial performance, prompting investors to closely monitor the company's future financial health and strategic adjustments.
See More
Acrivon Therapeutics Reports Promising Preclinical Results
- Clinical Trial Progress: Acrivon Therapeutics' ACR-368 demonstrates potent synergy with Topoisomerase 1 inhibitors in a registrational-intent Phase 2b study, indicating significant potential for enhancing treatment efficacy and improving patient outcomes in antibody-drug conjugates (ADCs).
- Immunotherapy Breakthrough: ACR-2316, when combined with anti-PD-L1, achieves complete and durable tumor regression in immunocompetent tumor mouse models, highlighting its potential value in immunotherapy and offering new treatment options for patients.
- AACR Conference Presentations: Acrivon will showcase three posters, including a late-breaking study, at the upcoming AACR Annual Meeting, further validating the unique advantages of its AP3 platform in identifying therapeutic candidates and combinations with significant clinical impact, potentially attracting more investor interest.
- FDA Fast Track Designation: ACR-368 has received Fast Track designation from the FDA based on its monotherapy potential in endometrial cancer patients, demonstrating the company's strategic positioning and competitiveness in the precision medicine market.
See More
FDA's Accelerated Approval Framework Drives Cancer Treatment Advances
- Clinical Survival Rate Improvement: A January 2026 analysis confirmed that drugs approved through the FDA's accelerated pathway improved progression-free survival in 65% of solid tumor indications, demonstrating significant clinical efficacy and driving clinical-stage oncology companies toward registration-directed study designs in high-unmet-need tumor types.
- Fast Track Designation: Oncolytics Biotech's cancer treatment pelareorep received FDA Fast Track designation for KRAS-mutant microsatellite-stable metastatic colorectal cancer patients, achieving a 33% response rate in combination with standard chemotherapy, significantly higher than the 10% response rate with standard treatment, and a median survival of 27 months compared to 11.2 months with standard care.
- Substantial Market Potential: The second-line treatment market for KRAS-mutant microsatellite-stable colorectal cancer patients is estimated to be between $3 billion and $5 billion annually, with Oncolytics Biotech planning a controlled study to compare standard care versus standard care plus pelareorep, further validating its therapeutic advantage in this high-demand area.
- Team Expansion and Strategic Positioning: Oncolytics Biotech recently appointed two key executives to support its expansion plans, with CEO Jared Kelly emphasizing that the success of pelareorep in clinical trials will present significant market opportunities, particularly in cancer areas lacking effective treatment options.
See More
Oncolytics Biotech Strengthens Leadership Amid Oncology Market Surge
- Executive Appointments: Oncolytics Biotech has appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics, both bringing extensive experience in late-stage oncology trial execution and regulatory strategy to advance the company's registration-directed programs in gastrointestinal cancers.
- Clinical Data Breakthrough: The company reported that pelareorep achieved a 33% objective response rate in second-line KRAS-mutant microsatellite stable metastatic colorectal cancer patients when combined with standard chemotherapy, tripling the historical response rate of 6-11%, demonstrating significant efficacy in this difficult-to-treat population.
- FDA Alignment Success: Oncolytics has secured FDA alignment on its Phase 3 study design for pelareorep in first-line metastatic pancreatic cancer, positioning it to launch the only immunotherapy registration trial currently planned for this challenging therapeutic area, further solidifying its market position.
- Strategic Expansion: The company has also expanded its Scientific Advisory Board with globally recognized experts from Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center, aiming to accelerate clinical development across multiple indications and enhance overall R&D capabilities.
See More
Oncolytics Biotech Strengthens Leadership to Advance Clinical Programs
- Leadership Enhancement: Oncolytics Biotech has appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics, both bringing extensive experience in late-stage oncology trial execution and regulatory strategy to advance the company's registration-directed programs in gastrointestinal cancers.
- Breakthrough Efficacy Data: The company reported that pelareorep achieved a 33% objective response rate in second-line KRAS-mutant microsatellite stable metastatic colorectal cancer patients when combined with standard chemotherapy, significantly surpassing the historical 6-11% response rate, indicating its potential in difficult-to-treat patient populations.
- FDA Designation Approval: Oncolytics secured FDA alignment on its Phase 3 study design for pelareorep in first-line metastatic pancreatic cancer, marking the initiation of the only immunotherapy registration trial planned for this challenging area, further solidifying its market position.
- Advisory Board Expansion: The company has expanded its Scientific Advisory Board by adding globally recognized experts from Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center, laying the groundwork for accelerated clinical development across multiple indications.
See More
ScinoPharm Secures FDA Approval for Glatiramer Acetate Injection in Multiple Sclerosis
- FDA Approval: ScinoPharm Taiwan (TWSE:1789) received FDA approval for its Glatiramer Acetate Injection for treating adult multiple sclerosis patients, marking the company's first finished drug approval and paving the way for regulatory submissions in Europe and Asia for broader commercialization.
- Market Reaction: Following this announcement, ScinoPharm's stock price rose by 3.08% to NT$23.40 on January 8, 2025, reflecting positive market sentiment regarding the product's prospects.
- Clinical Trial Progress: The approval supports the company's competitiveness in the global market, as Glatiramer Acetate remains a key product despite revenue erosion from generics, highlighting its ongoing relevance in the biotech sector.
- Strategic Positioning: This approval not only strengthens ScinoPharm's position in the biopharmaceutical landscape but also lays the groundwork for future market expansions, demonstrating the company's commitment to innovative drug development.
See More
Acrivon Therapeutics Q4 Earnings Miss Expectations
- Earnings Report: Acrivon Therapeutics reported a Q4 GAAP EPS of -$0.49, missing expectations by $0.01, indicating ongoing challenges in profitability that may affect investor confidence.
- Cash Reserves: As of December 31, 2025, the company had $118.6 million in cash, cash equivalents, and marketable securities, expected to fund operations into Q2 2027, suggesting adequate liquidity in the short term.
- Conference Presentations: Acrivon presented at the TD Cowen 46th Annual Health Care Conference and the ESGO 27th Annual Congress, aiming to enhance visibility among investors and the industry, potentially creating future financing opportunities.
- Market Attention: Seeking Alpha's Quant Rating on Acrivon Therapeutics reflects market scrutiny of its financial performance, prompting investors to closely monitor the company's future financial health and strategic adjustments.
See More
Acrivon Therapeutics Reports Promising Preclinical Results
- Clinical Trial Progress: Acrivon Therapeutics' ACR-368 demonstrates potent synergy with Topoisomerase 1 inhibitors in a registrational-intent Phase 2b study, indicating significant potential for enhancing treatment efficacy and improving patient outcomes in antibody-drug conjugates (ADCs).
- Immunotherapy Breakthrough: ACR-2316, when combined with anti-PD-L1, achieves complete and durable tumor regression in immunocompetent tumor mouse models, highlighting its potential value in immunotherapy and offering new treatment options for patients.
- AACR Conference Presentations: Acrivon will showcase three posters, including a late-breaking study, at the upcoming AACR Annual Meeting, further validating the unique advantages of its AP3 platform in identifying therapeutic candidates and combinations with significant clinical impact, potentially attracting more investor interest.
- FDA Fast Track Designation: ACR-368 has received Fast Track designation from the FDA based on its monotherapy potential in endometrial cancer patients, demonstrating the company's strategic positioning and competitiveness in the precision medicine market.
See More
FDA's Accelerated Approval Framework Drives Cancer Treatment Advances
- Clinical Survival Rate Improvement: A January 2026 analysis confirmed that drugs approved through the FDA's accelerated pathway improved progression-free survival in 65% of solid tumor indications, demonstrating significant clinical efficacy and driving clinical-stage oncology companies toward registration-directed study designs in high-unmet-need tumor types.
- Fast Track Designation: Oncolytics Biotech's cancer treatment pelareorep received FDA Fast Track designation for KRAS-mutant microsatellite-stable metastatic colorectal cancer patients, achieving a 33% response rate in combination with standard chemotherapy, significantly higher than the 10% response rate with standard treatment, and a median survival of 27 months compared to 11.2 months with standard care.
- Substantial Market Potential: The second-line treatment market for KRAS-mutant microsatellite-stable colorectal cancer patients is estimated to be between $3 billion and $5 billion annually, with Oncolytics Biotech planning a controlled study to compare standard care versus standard care plus pelareorep, further validating its therapeutic advantage in this high-demand area.
- Team Expansion and Strategic Positioning: Oncolytics Biotech recently appointed two key executives to support its expansion plans, with CEO Jared Kelly emphasizing that the success of pelareorep in clinical trials will present significant market opportunities, particularly in cancer areas lacking effective treatment options.
See More
Oncolytics Biotech Strengthens Leadership Amid Oncology Market Surge
- Executive Appointments: Oncolytics Biotech has appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics, both bringing extensive experience in late-stage oncology trial execution and regulatory strategy to advance the company's registration-directed programs in gastrointestinal cancers.
- Clinical Data Breakthrough: The company reported that pelareorep achieved a 33% objective response rate in second-line KRAS-mutant microsatellite stable metastatic colorectal cancer patients when combined with standard chemotherapy, tripling the historical response rate of 6-11%, demonstrating significant efficacy in this difficult-to-treat population.
- FDA Alignment Success: Oncolytics has secured FDA alignment on its Phase 3 study design for pelareorep in first-line metastatic pancreatic cancer, positioning it to launch the only immunotherapy registration trial currently planned for this challenging therapeutic area, further solidifying its market position.
- Strategic Expansion: The company has also expanded its Scientific Advisory Board with globally recognized experts from Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center, aiming to accelerate clinical development across multiple indications and enhance overall R&D capabilities.
See More
Oncolytics Biotech Strengthens Leadership to Advance Clinical Programs
- Leadership Enhancement: Oncolytics Biotech has appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics, both bringing extensive experience in late-stage oncology trial execution and regulatory strategy to advance the company's registration-directed programs in gastrointestinal cancers.
- Breakthrough Efficacy Data: The company reported that pelareorep achieved a 33% objective response rate in second-line KRAS-mutant microsatellite stable metastatic colorectal cancer patients when combined with standard chemotherapy, significantly surpassing the historical 6-11% response rate, indicating its potential in difficult-to-treat patient populations.
- FDA Designation Approval: Oncolytics secured FDA alignment on its Phase 3 study design for pelareorep in first-line metastatic pancreatic cancer, marking the initiation of the only immunotherapy registration trial planned for this challenging area, further solidifying its market position.
- Advisory Board Expansion: The company has expanded its Scientific Advisory Board by adding globally recognized experts from Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center, laying the groundwork for accelerated clinical development across multiple indications.
See More
ScinoPharm Secures FDA Approval for Glatiramer Acetate Injection in Multiple Sclerosis
- FDA Approval: ScinoPharm Taiwan (TWSE:1789) received FDA approval for its Glatiramer Acetate Injection for treating adult multiple sclerosis patients, marking the company's first finished drug approval and paving the way for regulatory submissions in Europe and Asia for broader commercialization.
- Market Reaction: Following this announcement, ScinoPharm's stock price rose by 3.08% to NT$23.40 on January 8, 2025, reflecting positive market sentiment regarding the product's prospects.
- Clinical Trial Progress: The approval supports the company's competitiveness in the global market, as Glatiramer Acetate remains a key product despite revenue erosion from generics, highlighting its ongoing relevance in the biotech sector.
- Strategic Positioning: This approval not only strengthens ScinoPharm's position in the biopharmaceutical landscape but also lays the groundwork for future market expansions, demonstrating the company's commitment to innovative drug development.
See More
